Azurity Pharma Trials - LARVOL Sigma

46 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Nxera Pharma

2013-001445-13: Assessment of the early bronchodilation of Glycopyrronium bromide compared to Tiotropium in patients with moderate to severe COPD

Not yet recruiting

150

Europe

Glycopyrronium bromide, Spiriva Handihaler, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler, Spiriva Handihaler

Novartis Pharma GmbH, Novartis Pharma GmbH

Chronic Obstructive Pulmonary Disease (COPD), COPD is a chronic condition of the lungs which causes people to suffer symptoms such as shortness of breath and coughing., Diseases [C] - Respiratory Tract Diseases [C08]

2021-004972-32: Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children (6 to less than 12 years) with asthma. Farmacocinética, farmacodinámica, seguridad y tolerabilidad de bromuro de glicopirronio en niños con asma (de 6 a menos de 12 años de edad).

Ongoing

Europe, RoW

Glycopyrronium bromide 25 μg of active moiety in the capsule, Glycopyrronium bromide 12.5 μg of active moiety in the capsule, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler

Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG

Asthma Asma, Asthma Asma, Diseases [C] - Respiratory Tract Diseases [C08]

NCT05222529 / 2021-004972-32: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Recruiting

Europe, RoW

Glycopyrronium bromide 25ug, NVA237, Placebo, Glycopyrronium bromide 12.5ug

Novartis Pharmaceuticals, Novartis Pharma AG

Asthma

06/25

Ultibro (glycopyrronium/indacaterol) / Novartis

2016-001435-13: Description of the ability to learn how to handle inhaler devices in COPD Etude descriptive de la capacité d’apprendre à utiliser des systèmes d’inhalation dans la bronchopneumopathie chronique obstructive

Ongoing

Europe

Inhalation powder, hard capsule, Inhalation solution, Inhalation powder, pre-dispensed, Ultibro® Breezhaler® 110/50 μg, Spiriva® Respimat® 2,5 μg, Seretide® Diskus® 500/50 μg

CHU de Bordeaux, CHU de Bordeaux

Chronic Obstructive Pulmonary Disease (COPD) Bronchopneumopathie chronique obstructive (BPCO), Chronic Obstructive Pulmonary Disease (COPD) Bronchopneumopathie chronique obstructive (BPCO), Diseases [C] - Respiratory Tract Diseases [C08]

2015-000473-12: The effectiveness of single dose Ultibro by Breezhaler versus ipratropium/salbutamol by nebulizer

Not yet recruiting

Europe

indacaterol maleate/glycopyrronium bromide, ipratropium/salbutamol, QVA149, Inhalation powder, hard capsule, Nebuliser liquid, Ultibro Breezhaler (indacaterol/glycopyrronium), Combivent, salbutamol/ipratropium

UMCG, UMCG, Novartis

COPD, chronic obstructive pulmonary disease, COPD, chronic obstructive pulmonary disease, Diseases [C] - Respiratory Tract Diseases [C08]

2019-003351-11: Study to the effects of using "triple therapy" on the health status of COPD patients with characteristics of asthma Een onderzoek naar het effect van het gebruik van “triple therapie” op de gezondheids-status van COPD-patiënten met kenmerken van asthma

Not yet recruiting

316

Europe

Trimbow, Pressurised inhalation, Inhalation powder, Trimbow, Anoro or Duaklir Genuair Inhalationpowder or Ultibro Breezhaler or Spiolto Respimat

GPRI, General Practitioners Research Institute (GPRI)

Chronic Obstructive Pulmonary Disease (COPD) patients COPD patiënten, COPD COPD, Diseases [C] - Respiratory Tract Diseases [C08]

ChiCTR2100043128: Efficacy and cardiovascular adverse effects of Long-acting inhaled dual bronchodilation

Recruiting

receive QVA149 110/50 mg ;receive Tiotropium 18 μg

The First Affiliated Hospital of Shantou University Medical College; The First Affiliated Hospital of Shantou University Medical College, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College

Chronic Obstructive Pulmonary Disease

ANTES B+, NCT06282861: Clinical Trial

Recruiting

1028

Europe

Trelegy Ellipta 100/62.5/25Mcg Inh 30D, LABA/LAMA/ICS, Brimica, LABA/LAMA, Duaklir, Ultibro, Ulunar, Xoterna, Anoro, Laventair, Spiolto Respimat, Yanimo, Foradil, LABA, Broncoral, Formoterol stada, Oxis, Formatris, Formoterol Aldo, Onbrez, Oslif, Hirobriz, Striverdi, Beglan, Betamican, Inaspir, Serevent, Soltel, Eklira, LAMA, Bretaris, Seebri, Tovanor, Enurev, Spiriva, Tavulus, Sirkava, Braltus, Gregal, Incruse, Rolufta

Fundacio Privada Mon Clinic Barcelona, GlaxoSmithKline

Chronic Obstructive Pulmonary Disease

09/25

Pulmonary function and treatment in patients with pulmonary hypertension, ChiCTR2200063362: The pulmonary function / airway resistance and treatment in patients with pulmonary hypertension

Not yet recruiting

100

indacaterol/glycopyrronium bromide powder for inhalation ;the conventional treatment of pulmonary hypertension

Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, self-financing

pulmonary hypertension

NCT06643078: A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Recruiting

474

RoW

HL231 Solution for Inhalation, Ultibro 110μg/50 μg

Haisco Pharmaceutical Group Co., Ltd., Sichuan Haisco Pharmaceutical Group Co., Ltd

Chronic Obstructive Pulmonary Disease (COPD)

10/25

ChiCTR2300068316: A multicenter, randomized, placebo-controlled clinical study to evaluate the safety and efficacy of HL231 inhalation solution in the treatment of chronic obstructive pulmonary disease (COPD)

Not yet recruiting

B, F, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, B, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, D, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;D, F, B (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;F, B, D (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution) ;B, D, F (B: 261 μg/141 μg HL231 inhalation solution; D: Jierun Ultibro 110 μg/50 μg); F: 261 μg/120 μg HL231 inhalation solution)

West China Hospital, Sichuan University; West China Hospital, Sichuan University, Haisco Pharmaceutical Group Co., Ltd.

Chronic obstructive pulmonary disease (COPD)

NCT06035393: A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting

200

RoW

HRG2005 inhalation, Placebo to match HRG2005 inhalation, Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation, Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Jiangsu HengRui Medicine Co., Ltd.

Chronic Obstructive Pulmonary Disease

08/25

Horizant (gabapentin enacarbil XR) / Azurity Pharma, Astellas, GSK

NCT06247488: Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

Completed

110

Placebo, matching over-encapsulated capsule, Oxycodone 20 mg, Oxycontin, GE-IR 200 mg, Gabapentin Enacarbil, Horizant, GE-IR 450 mg

Arbor Pharmaceuticals, Inc.

Abuse Potential

04/23

NCT06097676: An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Completed

Placebo, Alprazolam 2 mg, Xanax, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Horizant, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg

Arbor Pharmaceuticals, Inc.

Abuse Potential

06/22

NCT03082755: Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Recruiting

156

Gabapentin Enacarbil, Horizant, Placebo Oral Tablet, Placebo

University of Texas at Austin, National Institute on Aging (NIA)

Alzheimer Disease

08/22

03/23

NCT02560766: An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

132

HORIZANT 300 mg, Gabapentin Enacarbil Extended-Release Tablets, HORIZANT 600 mg, Placebo

XenoPort, Inc.

RLS

10/23

NCT02633683: An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

144

HORIZANT 600 mg, Gabapentin Enacarbil Extended-Release Tablets

XenoPort, Inc.

RLS

05/24

07/24

Alvesco (ciclesonide) / Teijin, Korea University Medical Center, Azurity Pharma

2006-002450-30: An Open label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide /Salmeterol in Symptomatic Asthmatics

Ongoing

Europe

Alvesco 160 inhaler, Flixotide Accuhaler, Alvesco 160 inhaler, Flixotide Accuhaler

Hull and East Yorkshire Hospitals Trust

Chronic asthma

NCT03141424: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Completed

Europe

Tapering of inhaled corticosteroid (ICS) treatment, budesonide, fluticasone proprionate, mometasone furoate, beclometasone dipropionate, ciclesonide

Hvidovre University Hospital

Asthma

10/24

PROTECT-V, NCT04870333 / 2020-004144-28: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Recruiting

2/3

5000

Europe

Niclosamide, Placebo, Ciclesonide, Sotrovimab

Cambridge University Hospitals NHS Foundation Trust, Life Arc, Kidney Research UK (KRUK), UNION therapeutics, Addenbrookes Charitable Trust, GlaxoSmithKline, National Institute for Health Research, United Kingdom

Covid19

07/24

12/24

2004-001838-16: Efficacy and safety of a fixed combination of ciclesonide and formoterol once or twice daily in the treatment of persistent asthma A randomized, double-blind, placebo-controlled, parallel-group, multi-center study

Ongoing

100

Europe

Ciclesonide/Formoterol Fixed Combination, Ciclesonide-Mono DPI, BY9010,

ALTANA Pharma AG

asthma bronchiale

2020-001928-34: Treatment with inhalation of Ciclesonide for patients with coronavirus disease: A randomised open study. Behandling med inhalation av Ciklesonid till patienter med coronavirussjukdom: En randomiserad oblindad behandlingsstudie.

Ongoing

446

Europe

Pressurised inhalation, solution, Alvesco

Capio S:t Görans Sjukhus, Axel och Margaret Ax:son Johnsons stiftelse för allmännyttiga ändamål

Covid-19 pneumonia, Coronavirus disease, Diseases [C] - Virus Diseases [C02]

HALT, NCT04381364: Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study ( COVID-19)

Active, not recruiting

Europe

Ciclesonide Inhalation Aerosol, Alvesco

Ola Blennow, MD, PhD, Karolinska University Hospital, Danderyd Hospital, Centrallasarettet Västerås

Covid-19, Pneumonia, Viral, Sars-CoV2

08/21

01/22

2020-002208-37: CIMMCov: A randomized clinical study for prevention of severe disease in mild-to-moderate COVID-19 patients, using the inhaled medication Ciclesonide. CIMMCov: Et randomiseret klinisk studie for forebyggelse af forværring af mild til moderat COVID-19-sygdom ved brug af inhalationsmedicinen Ciclesonid.

Not yet recruiting

138

Europe

Alvesco, 081801, Inhalation vapour, liquid, Alvesco

Respiratory Research Unit 237, Hvidovre Hospital, Covis Pharma

COVID-19 pneumonia, Coronavirus (COVID-19) infection in the lungs, Diseases [C] - Respiratory Tract Diseases [C08]

NCT06589245: Inhaled Ciclesonide Study in Preterm Infants

Not yet recruiting

Alvesco Inhalant Product, ciclesonide

Children's Mercy Hospital Kansas City, University of Pittsburgh, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Bronchopulmonary Dysplasia

08/26

Feraheme (ferumoxytol injection) / Azurity Pharma

AMAGFeraheme, NCT04080908: Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

Terminated

Ferumoxytol injection

NYU Langone Health

Anemia

10/21

NCT06110494: A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

Completed

Iron oxide nanoparticles treatment Ferumoxytol/H2O2, Fer, Feraheme, NaOCl, Sodium Hypochlorite, Active comparator, NaCl, Placebo comparator, saline, supplementary irrigation, NaOCl with passive ultrasonic activation, adjunctive irrigation step

University of Pennsylvania

Apical Periodontitis, Pulp Disease, Dental

03/22

EASI-A, NCT04278651: Early Antenatal Support for Iron Deficiency Anemia

Recruiting

Ferumoxytol, Ferrous Sulfate

Thomas Jefferson University, Auerbach Hematology and Oncology

Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy

08/25

12/25

NCT04205266: IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Recruiting

Ferumoxytol, Feraheme, Ferrous Sulfate, oral iron

Thomas Jefferson University, AMAG Pharmaceuticals, Inc.

Anemia, Iron Deficiency, Heavy Menstrual Bleeding

01/25

2018-004304-19: Research study to evaluate the experimental drug ferumoxytol, to see how well it works for children with iron deficiency anemia (IDA) or who are at risk of developing IDA, and to see how safe it is compared to another marketed iron product – iron sucrose.

Not yet recruiting

Europe

Ferumoxytol, Solution for injection, Feraheme®, Venofer®

AMAG Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia (IDA) in Pediatric Subjects, Iron Deficiency Anemia (IDA) in Pediatric Subjects, Diseases [C] - Nutritional and Metabolic Diseases [C18]

NCT03619850 / 2017-004026-15: A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Recruiting

129

Europe, US, RoW

Ferumoxytol, Feraheme, Iron sucrose, Venofer

AMAG Pharmaceuticals, Inc.

Chronic Kidney Disease; Iron Deficiency Anemia

08/24

NCT04268849: Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Recruiting

104

Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C

Auerbach Hematology Oncology Associates P C, AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia

11/23

02/24

NCT04253626: Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

Completed

Ferumoxytol Injection [Feraheme], Ferrous Sulfate

Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Pregnancy Related, Anemia, Iron Deficiency

07/24

NCT03893045 / 2018-004304-19: A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Recruiting

Europe, US

ferumoxytol, Feraheme, Iron sucrose, Venofer

AMAG Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia

07/25

10/25

DIVI, NCT05340465: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Recruiting

120

Darbepoetin Alfa, Aranesp, Darbe, Low Molecular Weight Iron Dextran, INFeD, LMW-ID, Ferumoxytol injection, Feraheme, FMX, Oral iron supplements, Ferr-in-sol

University of Washington, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption

12/25

12/27

XACT-Fe-GBM-01, NCT04900792: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Active, not recruiting

Ferumoxytol injection, Feraheme, Ferumoxytol, Pharmacological ascorbate, ASCOR, vitamin C, ascorbic acid, External beam radiation therapy, EBRT, radiotherapy, VMAT, Temozolomide, Temodar, temozolomide capsule

Bryan Allen, Holden Comprehensive Cancer Center, National Cancer Institute (NCI)

Glioblastoma, Glioblastoma Multiforme

06/25

12/26

BiDil (hydralazine/isosorbide dinitrate) / Azurity Pharma

DANHEART, NCT03514108 / 2015-002150-12: (H-HeFT and Met-HeFT)

Recruiting

1500

Europe

Hydralazine Isosorbide Dinitrate, BiDil, Placebo Oral Tablet, Metformin Hydrochloride

Henrik Wiggers, Danish Heart Foundation, Danish Council for Independent Research, The Danish Regions: Foundation for Medical Research, The Novo Nordisk Foundation, The Aase og Ejnar Danielsen Foundation

Heart Failure, Diabetes

12/26

GRAHF-2, NCT02305095: Genomic Response Analysis of Heart Failure Therapy in African Americans

Completed

N/A

225

FDC I/H, BiDil

University of Pittsburgh

Heart Failure

12/20

09/22

Xatmep (methotrexate oral solution) / Azurity Pharma

SWOG-S1318, NCT02143414: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active, not recruiting

Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Echocardiography, EC, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mercaptopurine, 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-Mercaptopurine, 6-Mercaptopurine Monohydrate, 6-MP, 6-Purinethiol, 6-Thiopurine, 6-Thioxopurine, 6H-Purine-6-thione, 1,7-dihydro- (9CI), 7-Mercapto-1,3,4,6-tetrazaindene, Alti-Mercaptopurine, Azathiopurine, Bw 57-323H, Flocofil, Ismipur, Leukerin, Leupurin, Mercaleukim, Mercaleukin, Mercaptina, Mercaptopurinum, Mercapurin, Mern, NCI-C04886, Puri-Nethol, Purimethol, Purine, 6-mercapto-, Purine-6-thiol (8CI), Purine-6-thiol, monohydrate, Purinethiol, Purinethol, U-4748, WR-2785, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Methotrexate Sodium, Sodium Methotrexate, Trexall, Xatmep, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine, LCR, Leurocristine, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray

National Cancer Institute (NCI)

Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia

06/22

10/25

NCT06207123: A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting

1/2

LP-118, Ponatinib, Iclusig, Vincristine, Oncovin, Vincrex, Vincasar PES, Dexamethasone, DexPak, Decadron, Methotrexate, Otrexup, Xatmep, Rasuvo

University of Chicago

Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma

12/26

NCT05543122: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Completed

N/A

Canada

either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe, Typical brand names include, but not limited to: Tenoretic, Wellbutrin, Zyban, Briviact, Cipralex, Lexapro, Diflucan, Vimpat, Lamictal, Keppra, Trexall, Xatmep, Ezetrol, Nexlizet

The Hospital for Sick Children, St. Justine's Hospital, University of Waterloo

Breast Feeding

12/23

03/24

Ciraparantag (aripazine) / Norgine, Azurity Pharma

NCT04593784: Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Recruiting

108

Ciraparantag, PER977, AMAG 977, Placebo, PBO, Point-of-Care Coagulometer (investigational device), Coagulometer

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Healthy

12/24

zonisamide oral suspension (ET-104) / Eton Pharma, Azurity Pharma

NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Not yet recruiting

Zonisamide Oral Product, ZONISADE, Zonisamide oral suspension

Azurity Pharmaceuticals

Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy

03/26

Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma

2008-003905-15: Carmustine implant (Gliadel Wafer) plus adjuvant and concomitant Temozolomide in combination with radiotherapy in primary glioblastoma patients.

Ongoing

105

Europe

TEMODAL*1FL 5CPS 20MG, GLIADEL*8 IMPIANTI 7,7MG, TEMODAL*1FL 5CPS 20MG, GLIADEL*8 IMPIANTI 7,7MG

ISTITUTO NEUROLOGICO \"CARLO BESTA\"

glioblastoma recurrent

NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting

100

Carmustine 7.7Mg Wafer, GLIADEL

University of Nebraska, Arbor Pharmaceuticals, Inc.

Brain Tumor - Metastatic

12/27

12/28

VIGILANT, NCT02684838: Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Active, not recruiting

N/A

272

Arbor Pharmaceuticals, Inc.

CNS Tumor

12/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Nxera Pharma

2013-001445-13: Assessment of the early bronchodilation of Glycopyrronium bromide compared to Tiotropium in patients with moderate to severe COPD

Not yet recruiting

150

Europe

Glycopyrronium bromide, Spiriva Handihaler, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler, Spiriva Handihaler

Novartis Pharma GmbH, Novartis Pharma GmbH

Ongoing

Europe, RoW

Glycopyrronium bromide 25 μg of active moiety in the capsule, Glycopyrronium bromide 12.5 μg of active moiety in the capsule, NVA237, Inhalation powder, hard capsule, Seebri Breezhaler

Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG

Asthma Asma, Asthma Asma, Diseases [C] - Respiratory Tract Diseases [C08]

NCT05222529 / 2021-004972-32: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Recruiting

Europe, RoW

Glycopyrronium bromide 25ug, NVA237, Placebo, Glycopyrronium bromide 12.5ug

Novartis Pharmaceuticals, Novartis Pharma AG

Asthma

06/25

Ultibro (glycopyrronium/indacaterol) / Novartis

Ongoing

Europe

Inhalation powder, hard capsule, Inhalation solution, Inhalation powder, pre-dispensed, Ultibro® Breezhaler® 110/50 μg, Spiriva® Respimat® 2,5 μg, Seretide® Diskus® 500/50 μg

CHU de Bordeaux, CHU de Bordeaux

2015-000473-12: The effectiveness of single dose Ultibro by Breezhaler versus ipratropium/salbutamol by nebulizer

Not yet recruiting

Europe

UMCG, UMCG, Novartis

COPD, chronic obstructive pulmonary disease, COPD, chronic obstructive pulmonary disease, Diseases [C] - Respiratory Tract Diseases [C08]

Not yet recruiting

316

Europe

Trimbow, Pressurised inhalation, Inhalation powder, Trimbow, Anoro or Duaklir Genuair Inhalationpowder or Ultibro Breezhaler or Spiolto Respimat

GPRI, General Practitioners Research Institute (GPRI)

Chronic Obstructive Pulmonary Disease (COPD) patients COPD patiënten, COPD COPD, Diseases [C] - Respiratory Tract Diseases [C08]

ChiCTR2100043128: Efficacy and cardiovascular adverse effects of Long-acting inhaled dual bronchodilation

Recruiting

receive QVA149 110/50 mg ;receive Tiotropium 18 μg

Chronic Obstructive Pulmonary Disease

ANTES B+, NCT06282861: Clinical Trial

Recruiting

1028

Europe

Fundacio Privada Mon Clinic Barcelona, GlaxoSmithKline

Chronic Obstructive Pulmonary Disease

09/25

Pulmonary function and treatment in patients with pulmonary hypertension, ChiCTR2200063362: The pulmonary function / airway resistance and treatment in patients with pulmonary hypertension

Not yet recruiting

100

indacaterol/glycopyrronium bromide powder for inhalation ;the conventional treatment of pulmonary hypertension

Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, self-financing

pulmonary hypertension

NCT06643078: A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD

Recruiting

474

RoW

HL231 Solution for Inhalation, Ultibro 110μg/50 μg

Haisco Pharmaceutical Group Co., Ltd., Sichuan Haisco Pharmaceutical Group Co., Ltd

Chronic Obstructive Pulmonary Disease (COPD)

10/25

Not yet recruiting

West China Hospital, Sichuan University; West China Hospital, Sichuan University, Haisco Pharmaceutical Group Co., Ltd.

Chronic obstructive pulmonary disease (COPD)

NCT06035393: A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Recruiting

200

RoW

Jiangsu HengRui Medicine Co., Ltd.

Chronic Obstructive Pulmonary Disease

08/25

Horizant (gabapentin enacarbil XR) / Azurity Pharma, Astellas, GSK

NCT06247488: Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

Completed

110

Placebo, matching over-encapsulated capsule, Oxycodone 20 mg, Oxycontin, GE-IR 200 mg, Gabapentin Enacarbil, Horizant, GE-IR 450 mg

Arbor Pharmaceuticals, Inc.

Abuse Potential

04/23

NCT06097676: An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Completed

Arbor Pharmaceuticals, Inc.

Abuse Potential

06/22

NCT03082755: Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease

Recruiting

156

Gabapentin Enacarbil, Horizant, Placebo Oral Tablet, Placebo

University of Texas at Austin, National Institute on Aging (NIA)

Alzheimer Disease

08/22

03/23

NCT02560766: An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

132

HORIZANT 300 mg, Gabapentin Enacarbil Extended-Release Tablets, HORIZANT 600 mg, Placebo

XenoPort, Inc.

RLS

10/23

NCT02633683: An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

Recruiting

144

HORIZANT 600 mg, Gabapentin Enacarbil Extended-Release Tablets

XenoPort, Inc.

RLS

05/24

07/24

Alvesco (ciclesonide) / Teijin, Korea University Medical Center, Azurity Pharma

2006-002450-30: An Open label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide /Salmeterol in Symptomatic Asthmatics

Ongoing

Europe

Alvesco 160 inhaler, Flixotide Accuhaler, Alvesco 160 inhaler, Flixotide Accuhaler

Hull and East Yorkshire Hospitals Trust

Chronic asthma

NCT03141424: Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma

Completed

Europe

Tapering of inhaled corticosteroid (ICS) treatment, budesonide, fluticasone proprionate, mometasone furoate, beclometasone dipropionate, ciclesonide

Hvidovre University Hospital

Asthma

10/24

PROTECT-V, NCT04870333 / 2020-004144-28: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Recruiting

2/3

5000

Europe

Niclosamide, Placebo, Ciclesonide, Sotrovimab

Covid19

07/24

12/24

Ongoing

100

Europe

Ciclesonide/Formoterol Fixed Combination, Ciclesonide-Mono DPI, BY9010,

ALTANA Pharma AG

asthma bronchiale

Ongoing

446

Europe

Pressurised inhalation, solution, Alvesco

Capio S:t Görans Sjukhus, Axel och Margaret Ax:son Johnsons stiftelse för allmännyttiga ändamål

Covid-19 pneumonia, Coronavirus disease, Diseases [C] - Virus Diseases [C02]

HALT, NCT04381364: Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study ( COVID-19)

Active, not recruiting

Europe

Ciclesonide Inhalation Aerosol, Alvesco

Ola Blennow, MD, PhD, Karolinska University Hospital, Danderyd Hospital, Centrallasarettet Västerås

Covid-19, Pneumonia, Viral, Sars-CoV2

08/21

01/22

Not yet recruiting

138

Europe

Alvesco, 081801, Inhalation vapour, liquid, Alvesco

Respiratory Research Unit 237, Hvidovre Hospital, Covis Pharma

COVID-19 pneumonia, Coronavirus (COVID-19) infection in the lungs, Diseases [C] - Respiratory Tract Diseases [C08]

NCT06589245: Inhaled Ciclesonide Study in Preterm Infants

Not yet recruiting

Alvesco Inhalant Product, ciclesonide

Children's Mercy Hospital Kansas City, University of Pittsburgh, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Bronchopulmonary Dysplasia

08/26

Feraheme (ferumoxytol injection) / Azurity Pharma

AMAGFeraheme, NCT04080908: Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support

Terminated

Ferumoxytol injection

NYU Langone Health

Anemia

10/21

NCT06110494: A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

Completed

University of Pennsylvania

Apical Periodontitis, Pulp Disease, Dental

03/22

EASI-A, NCT04278651: Early Antenatal Support for Iron Deficiency Anemia

Recruiting

Ferumoxytol, Ferrous Sulfate

Thomas Jefferson University, Auerbach Hematology and Oncology

Pregnancy Related, Anemia, Iron Deficiency, Anemia of Pregnancy

08/25

12/25

NCT04205266: IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

Recruiting

Ferumoxytol, Feraheme, Ferrous Sulfate, oral iron

Thomas Jefferson University, AMAG Pharmaceuticals, Inc.

Anemia, Iron Deficiency, Heavy Menstrual Bleeding

01/25

Not yet recruiting

Europe

Ferumoxytol, Solution for injection, Feraheme®, Venofer®

AMAG Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia (IDA) in Pediatric Subjects, Iron Deficiency Anemia (IDA) in Pediatric Subjects, Diseases [C] - Nutritional and Metabolic Diseases [C18]

Recruiting

129

Europe, US, RoW

Ferumoxytol, Feraheme, Iron sucrose, Venofer

AMAG Pharmaceuticals, Inc.

Chronic Kidney Disease; Iron Deficiency Anemia

08/24

NCT04268849: Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Recruiting

104

Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C

Auerbach Hematology Oncology Associates P C, AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia

11/23

02/24

NCT04253626: Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia

Completed

Ferumoxytol Injection [Feraheme], Ferrous Sulfate

Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Pregnancy Related, Anemia, Iron Deficiency

07/24

NCT03893045 / 2018-004304-19: A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Recruiting

Europe, US

ferumoxytol, Feraheme, Iron sucrose, Venofer

AMAG Pharmaceuticals, Inc., AMAG Pharmaceuticals, Inc.

Iron Deficiency Anemia

07/25

10/25

DIVI, NCT05340465: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

Recruiting

120

Darbepoetin Alfa, Aranesp, Darbe, Low Molecular Weight Iron Dextran, INFeD, LMW-ID, Ferumoxytol injection, Feraheme, FMX, Oral iron supplements, Ferr-in-sol

University of Washington, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption

12/25

12/27

XACT-Fe-GBM-01, NCT04900792: A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Active, not recruiting

Bryan Allen, Holden Comprehensive Cancer Center, National Cancer Institute (NCI)

Glioblastoma, Glioblastoma Multiforme

06/25

12/26

BiDil (hydralazine/isosorbide dinitrate) / Azurity Pharma

DANHEART, NCT03514108 / 2015-002150-12: (H-HeFT and Met-HeFT)

Recruiting

1500

Europe

Hydralazine Isosorbide Dinitrate, BiDil, Placebo Oral Tablet, Metformin Hydrochloride

Heart Failure, Diabetes

12/26

GRAHF-2, NCT02305095: Genomic Response Analysis of Heart Failure Therapy in African Americans

Completed

N/A

225

FDC I/H, BiDil

University of Pittsburgh

Heart Failure

12/20

09/22

Xatmep (methotrexate oral solution) / Azurity Pharma

SWOG-S1318, NCT02143414: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active, not recruiting

National Cancer Institute (NCI)

06/22

10/25

NCT06207123: A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Recruiting

1/2

LP-118, Ponatinib, Iclusig, Vincristine, Oncovin, Vincrex, Vincasar PES, Dexamethasone, DexPak, Decadron, Methotrexate, Otrexup, Xatmep, Rasuvo

University of Chicago

Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma

12/26

NCT05543122: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants

Completed

N/A

Canada

The Hospital for Sick Children, St. Justine's Hospital, University of Waterloo

Breast Feeding

12/23

03/24

Ciraparantag (aripazine) / Norgine, Azurity Pharma

NCT04593784: Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Recruiting

108

Ciraparantag, PER977, AMAG 977, Placebo, PBO, Point-of-Care Coagulometer (investigational device), Coagulometer

Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.

Healthy

12/24

zonisamide oral suspension (ET-104) / Eton Pharma, Azurity Pharma

NCT06534502: Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

Not yet recruiting

Zonisamide Oral Product, ZONISADE, Zonisamide oral suspension

Azurity Pharmaceuticals

Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy

03/26

Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma

2008-003905-15: Carmustine implant (Gliadel Wafer) plus adjuvant and concomitant Temozolomide in combination with radiotherapy in primary glioblastoma patients.

Ongoing

105

Europe

TEMODAL*1FL 5CPS 20MG, GLIADEL*8 IMPIANTI 7,7MG, TEMODAL*1FL 5CPS 20MG, GLIADEL*8 IMPIANTI 7,7MG

ISTITUTO NEUROLOGICO \"CARLO BESTA\"

glioblastoma recurrent

NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting

100

Carmustine 7.7Mg Wafer, GLIADEL

University of Nebraska, Arbor Pharmaceuticals, Inc.

Brain Tumor - Metastatic

12/27

12/28

VIGILANT, NCT02684838: Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

Active, not recruiting

N/A

272

Arbor Pharmaceuticals, Inc.

CNS Tumor

12/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites